Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system

被引：0
作者：
Jing Huang
Yuntao Jia
Shusen Sun
Long Meng
机构：
[1] The First Affiliated Hospital of Chongqing Medical University,Department of Respiratory and Critical Care Medicine
[2] Children’s Hospital of Chongqing Medical University,Department of Pharmacy, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Ch
[3] Western New England University,Department of Pharmacy Practice, College of Pharmacy and Health Sciences
[4] Xiangya Hospital Central South University,Department of Pharmacy
[5] Central South University,Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital
[6] The First Affiliated Hospital of Chongqing Medical University,Department of Pharmacy
来源：
BMC Pharmacology and Toxicology | / 21卷
关键词：
Pharmacovigilance; Data mining; Dipeptidyl Peptidase-4 inhibitors; Adverse event reporting system;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 163 条
[11]  
Okuno Y(2016)OpenVigil FDA - Inspection of U.S. American Adverse Drug events pharmacovigilance data and novel clinical applications PloS one 11 319-635
[12]  
Sakaeda T(2019)Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS Clin Drug Invest 39 2405-436
[13]  
Kadoyama K(2018)Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance-pharmacodynamic study Br J Clin Pharmacol 84 39-607
[14]  
Okuno Y(2013)Disproportionality methods for pharmacovigilance in longitudinal observational databases Stat Methods Med Res 22 627-1568
[15]  
Singhal S(2014)Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area Eur J Clin Pharmacol 70 427-140
[16]  
Chakraborty B(2010)Quantitative signal detection using spontaneous ADR reporting Pharmacoepidemiol Drug Saf 18 600-353
[17]  
Carnovale C(2009)Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 30 1556-159
[18]  
Mazhar F(2006)Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 28 127-1629
[19]  
Arzenton E(2015)DPP-4 inhibitors: focus on safety Expert Opin Drug Saf 14 337-2571
[20]  
Fadini GP(2013)Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin Adv Ther 30 149-797
12345678910